Register
Community
Overview
Experts
Editors
Fellows
Code of conduct
Company
About Us
FAQs
Privacy Policy
Terms of Use
Careers
Programs
News
News Releases
Press Coverage
Publications
Blog
Contact Us
Sign in
Topics:
Breast Cancer
•
Medical Oncology
•
Triple negative
•
Breast Cancer, Metastatic
In which patients with metastatic TNBC would you use metronomic chemotherapy?
Related Questions
What strategies do you implement to control the nausea from Enhertu?
How should we think about endocrine resistance in patients with inherited germline mutations such as BRCA, CHEK2, etc.?
How would you manage new symptomatic brain metastases (10-15) in a young woman with HER2+ metastatic breast cancer?
What is your preferred adjuvant chemotherapy regimen for a patient with local recurrence of TNBC two years after completing neoadjuvant ddAC-T who declined prior adjuvant capecitabine?
Would you avoid chemotherapy in a postmenopausal woman (age 65+) with HR+/HER2 negative, breast cancer, T3, with Oncotype DX < 25?
In metastatic hormone receptor positive breast cancer, would you consider combination exemestane and CDK4/6 inhibitor if letrozole and anastrazole are not tolerated?
How would you treat a patient with symptomatic and rapidly progressing metastatic HR+, HER2 low breast cancer with PIK3CA WT, ESR1 mutated, TMB high after progression on CDK 4/6 inhibitor, a taxane, and T-DXd?
What would be your treatment approach in a premenopausal BRCA2+ patient with cT2N0 grade 2-3, ER negative, PR variably positive (30%; staining weak to high), HER2 negative breast cancer?
Would you offer neoadjuvant chemoimmunotherapy per KEYNOTE 522 for a patient with clinical stage IIB triple-negative breast cancer with apocrine histology or recommend surgery first?
What neoadjuvant chemotherapy regimen would you choose for a triple positive (ER+/PR+/HER2+) cT2N1 G3 breast cancer for an elderly patient (80 y/o)?
